each affirmed their earnings guidance Tuesday.
New York-based Pfizer sees earnings before items rising to $1.58 a share this year from $1.31 in 2001, in line with the consensus estimate, according to First Call.
The company is currently in the process of acquiring
. Excluding the impact of that, Pfizer said it expects per-share earnings to rise 16% annually from 2002 to 2004, with revenue rising in the double digits in 2002 and 11% annually from 2002 to 2004.
Bristol-Myers' outlook is more complicated but still in line with estimates. The company affirmed its own forecast for 2002 earnings of $1.69 to $1.81 a share before costs for inventory reduction, which it estimated at roughly 55 cents in 2002. That puts the bottom-line range at about $1.14 to $1.26, in line with the consensus analyst estimate of $1.21 a share.
Pfizer was recently down 20 cents to $30, while was off 49 cents to $25.46.